Articles tagged with: Carfilzomib

News»

[ by | Aug 26, 2013 12:41 pm | 3 Comments ]
Amgen To Acquire Onyx, Maker Of Kyprolis; What Does It Mean For The Myeloma Community?

Onyx Pharmaceuticals, the South San Francisco, California-based com­pany that developed and now mar­kets Kyprolis (carfilzomib), announced yesterday eve­ning that it is being acquired by Amgen.

Amgen (NASDAQ:AMGN), which is based outside of Los Angeles, is the world’s largest biotech company.

Within the multiple myeloma community, Amgen is known most for its anemia medications – Aranesp (darbe­poetin alfa) and Epogen (epoetin alfa, also mar­keted as Procrit and Eprex) – as well as its drugs that in­crease the body’s production of white blood cells – Neupogen (filgra­stim) and

Read the full story »

News»

[ by | Updated: Jun 19, 2013 11:10 pm | Comments Off ]
The European Hematology Association’s Annual Congress Starts Today: A Look At The Key Myeloma-Related Presentations (EHA 2013)

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA …

Read the full story »

News»

[ by and | Jun 11, 2013 5:47 pm | 5 Comments ]
ASCO 2013 And Multiple Myeloma: What Were The Highlights?

This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.

During the meeting, The Beacon published daily updates that provided over­views of the important multiple myeloma findings presented during the meeting.

Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate im­pli­ca­­tions for the treatment of multiple myeloma?  Did the research at the meeting represent a major step for­ward for myeloma …

Read the full story »

News»

[ by and | Jun 6, 2013 11:06 am | Comments Off ]
ASCO 2013 Multiple Myeloma Update – Day Four: Poster Presentations

This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday.

Monday was the busiest day at the meeting with regard to myeloma research.  It featured a session of oral presentations in the morning and a poster session in the afternoon.

This update summarizes the myeloma-related studies presented during the afternoon poster session, which was the final myeloma-related session of the meeting. An earlier article covered the findings from the oral presentations that were given in the morning.

Most of …

Read the full story »

News»

[ by | Updated: Jun 12, 2013 12:30 pm | 2 Comments ]
ASCO 2013 Multiple Myeloma Update – Day Four: Oral Presentations

This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.

Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about im­por­tant new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.

This article summarizes the most important findings from Monday's oral pre­sen­ta­tion session. A later article will cover the findings from the after­noon poster session.

The content in our daily updates is based …

Read the full story »